Pharmacological characterization novel tetrazole-substituted competitive N-methyl-D-aspartic acid short duration action study activity novel excitatory amino acid receptor antagonist cis- methyl acid first tetrazole-containing competitive N-methyl-D-aspartic acid NMDA antagonist NMDA receptor brain membranes vitro displacement nM appreciable affinity acid AMPA kainate binding assays nM vitro NMDA receptor antagonist activity selective inhibition NMDA-induced depolarization cortical wedges microM microM NMDA effective vivo systemic administration number animal models neonatal rats NMDA-induced convulsions mg/kg i.p short duration action hr pigeons mg/kg i.m behavioral suppressant effects mg/kg NMDA dose mg/kg phencyclidine-like catalepsy pigeons mice maximal electroshock-induced seizures doses mg/kg i.p horizontal screen performance mg/kg Cholinergic GABAergic neuronal degenerations striatal infusion NMDA single multiple i.p doses summary antagonist activity systemic administration potential therapeutic value conditions neuronal cell loss due NMDA receptor excitotoxicity short duration action compound advantageous neuroprotective agent treatment acute conditions cerebral ischemia 